Archive · 26 Jun 2025
Lupin Launches Generic Drug for Chronic Constipation in US
Lupin, a drug company, has released a generic version of Prucalopride tablets in the US.
These tablets help adults with a long-term constipation problem called chronic idiopathic constipation.
This new drug is just as good as the original medicine, Motegrity.
The US government gave Lupin permission to sell it, and it's expected to be a profitable product with an estimated annual sales of $184 million.
Lupin Ltd. launched a generic version of Prucalopride tablets in the US.
The drug treats chronic idiopathic constipation in adults.
The tablets are bioequivalent to Takeda Pharmaceuticals' Motegrity.
Lupin received USFDA approval for the drug.
Estimated annual sales in the US market are $184 million.
- Who
- Lupin Ltd. launched the drug.
- What
- Lupin launched its generic Prucalopride tablets for chronic idiopathic constipation.
- When
- The launch occurred after USFDA approval.
- Where
- The product is available in the US market.
- Why
- To treat chronic idiopathic constipation in adults.
Market Impact
Financial Opportunity
Market Presence
Market Impact
Lupin's launch provides a generic alternative for chronic constipation treatment.
Financial Opportunity
Sales are estimated at $184 million, suggesting a substantial market opportunity.
- Company
- Lupin Ltd.
- Drug Name
- Prucalopride Tablets
- Use
- Treatment of Chronic Idiopathic Constipation
- Approval Agency
- USFDA
- Comparable Drug
- Motegrity Tablets (Takeda Pharmaceuticals)
- Estimated US Market
- $184 million annually
